Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16444021rdf:typepubmed:Citationlld:pubmed
pubmed-article:16444021lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:16444021lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:16444021lifeskim:mentionsumls-concept:C0494165lld:lifeskim
pubmed-article:16444021lifeskim:mentionsumls-concept:C1527249lld:lifeskim
pubmed-article:16444021lifeskim:mentionsumls-concept:C0679199lld:lifeskim
pubmed-article:16444021pubmed:issue129lld:pubmed
pubmed-article:16444021pubmed:dateCreated2006-1-30lld:pubmed
pubmed-article:16444021pubmed:abstractTextRetrospective study was performed to evaluate the efficacy of combined methods of treatment in patients with colorectal cancer with hepatic metastases. 57 patients (I group - control) undergone regional chemotherapy (RC) with hepatic arterial or intraportal 5Fluorouracil (5FU). From 84 patients 48 (II group) undergone liver resection + RC (5FU), 24 (III group) - hepatic arterial embolization +RC (5FU), and 12(IV group) with multiple bilobar (<3 cm) metastases- alcoholization of metastatic nodules +RC (5FU). Overall 5-year survival for the II group was 14.8% without operative or postoperative deaths. The median survival was 19 months (range 13-27 months) and 21 months (range 15-26 months) for II and III groups respectively, which is not different from the survival rate of patients who received only RC. Although, quality of life was much better after combined treatment. Resection of colorectal liver metastases followed by regional chemotherapy can provide long-term survival in selected patients.lld:pubmed
pubmed-article:16444021pubmed:languageruslld:pubmed
pubmed-article:16444021pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16444021pubmed:citationSubsetIMlld:pubmed
pubmed-article:16444021pubmed:statusMEDLINElld:pubmed
pubmed-article:16444021pubmed:monthDeclld:pubmed
pubmed-article:16444021pubmed:issn1512-0112lld:pubmed
pubmed-article:16444021pubmed:authorpubmed-author:MosidzeB ABAlld:pubmed
pubmed-article:16444021pubmed:authorpubmed-author:Megrelishvili...lld:pubmed
pubmed-article:16444021pubmed:authorpubmed-author:Kalmakhelidze...lld:pubmed
pubmed-article:16444021pubmed:issnTypePrintlld:pubmed
pubmed-article:16444021pubmed:ownerNLMlld:pubmed
pubmed-article:16444021pubmed:authorsCompleteYlld:pubmed
pubmed-article:16444021pubmed:pagination19-22lld:pubmed
pubmed-article:16444021pubmed:dateRevised2008-5-21lld:pubmed
pubmed-article:16444021pubmed:meshHeadingpubmed-meshheading:16444021...lld:pubmed
pubmed-article:16444021pubmed:meshHeadingpubmed-meshheading:16444021...lld:pubmed
pubmed-article:16444021pubmed:meshHeadingpubmed-meshheading:16444021...lld:pubmed
pubmed-article:16444021pubmed:meshHeadingpubmed-meshheading:16444021...lld:pubmed
pubmed-article:16444021pubmed:meshHeadingpubmed-meshheading:16444021...lld:pubmed
pubmed-article:16444021pubmed:meshHeadingpubmed-meshheading:16444021...lld:pubmed
pubmed-article:16444021pubmed:meshHeadingpubmed-meshheading:16444021...lld:pubmed
pubmed-article:16444021pubmed:year2005lld:pubmed
pubmed-article:16444021pubmed:articleTitle[Strategy of treatment of patients with colorectal cancer with hepatic metastases].lld:pubmed
pubmed-article:16444021pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16444021pubmed:publicationTypeEnglish Abstractlld:pubmed